ARS Pharmaceuticals, Inc (SPRY NASDAQ) stock market data APIs
$9.956
-0.15(-1.5%)
as of February 6, 2026
Try our APIs with
free plan!
ARS Pharmaceuticals, Inc Financial Data Overview
Price chart is built with
Anychart
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
Prev. Close
9.956
Open
9.8027
High
9.9855
Low
9.7709
52 wk Range
6.66-18.9
Market Cap
991 M
Shares Outstanding
98 849 K
Revenue
143 M
EPS
-0.52
Beta
0.743
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with ARS Pharmaceuticals, Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ARS Pharmaceuticals, Inc data using free add-ons & libraries
Get ARS Pharmaceuticals, Inc Fundamental Data
ARS Pharmaceuticals, Inc Fundamental data includes:
- Net Revenue: 143 M
- EBITDA: -89 807 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-10
- EPS/Forecast: -0.46
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ARS Pharmaceuticals, Inc News
New
How Investors May Respond To ARS Pharmaceuticals (SPRY) Expanding EURneffy Pediatric Use Across Europe
ARS Pharmaceuticals recently reported that the European Medicines Agency’s CHMP issued a positive opinion to expand EURneffy’s marketing authorization to include a 1 mg nasal adrenaline spray for ...
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
ARS Pharmaceuticals, Inc. EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the ri...
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
ARS Pharmaceuticals, Inc. California joins 23 other states eligible to receive free neffy® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc...
Assessing ARS Pharmaceuticals (SPRY) Valuation After A 19.3% Single Day Share Price Jump
ARS Pharmaceuticals (SPRY) has attracted fresh attention after a strong single-day move, with the stock up 19.3% and solid gains over the past week, month, and past 3 months. See our latest analysis ...
Get ARS Pharmaceuticals, Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
